Shijiazhuang Yiling Pharmaceutical Co Ltd
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfec… Read more
Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) - Net Assets
Latest net assets as of September 2025: CN¥10.70 Billion CNY
Based on the latest financial reports, Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) has net assets worth CN¥10.70 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥14.22 Billion) and total liabilities (CN¥3.52 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥10.70 Billion |
| % of Total Assets | 75.23% |
| Annual Growth Rate | 20.99% |
| 5-Year Change | 14.33% |
| 10-Year Change | 111.34% |
| Growth Volatility | 57.1 |
Shijiazhuang Yiling Pharmaceutical Co Ltd - Net Assets Trend (2008–2024)
This chart illustrates how Shijiazhuang Yiling Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shijiazhuang Yiling Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual net assets of Shijiazhuang Yiling Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥10.20 Billion | -10.81% |
| 2023-12-31 | CN¥11.44 Billion | +4.65% |
| 2022-12-31 | CN¥10.93 Billion | +20.48% |
| 2021-12-31 | CN¥9.07 Billion | +1.67% |
| 2020-12-31 | CN¥8.92 Billion | +12.21% |
| 2019-12-31 | CN¥7.95 Billion | +5.14% |
| 2018-12-31 | CN¥7.56 Billion | +6.35% |
| 2017-12-31 | CN¥7.11 Billion | +33.36% |
| 2016-12-31 | CN¥5.33 Billion | +10.47% |
| 2015-12-31 | CN¥4.83 Billion | +6.00% |
| 2014-12-31 | CN¥4.55 Billion | +6.95% |
| 2013-12-31 | CN¥4.26 Billion | +10.75% |
| 2012-12-31 | CN¥3.84 Billion | +3.87% |
| 2011-12-31 | CN¥3.70 Billion | +239.28% |
| 2010-12-31 | CN¥1.09 Billion | +38.01% |
| 2009-12-31 | CN¥790.55 Million | +63.33% |
| 2008-12-31 | CN¥484.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shijiazhuang Yiling Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1874.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥5.28 Billion | 51.65% |
| Common Stock | CN¥1.67 Billion | 16.34% |
| Other Components | CN¥3.27 Billion | 32.01% |
| Total Equity | CN¥10.22 Billion | 100.00% |
Shijiazhuang Yiling Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Shijiazhuang Yiling Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xi an Bright Laser Tech Co Ltd
SHG:688333
|
$2.34 Billion |
|
Parq Arauco
SN:PARAUCO
|
$2.35 Billion |
|
Auras Technology Co Ltd
TWO:3324
|
$2.35 Billion |
|
Steven Madden Ltd
NASDAQ:SHOO
|
$2.35 Billion |
|
DTZNY
OTCQB:DTZNY
|
$2.34 Billion |
|
Pharmaron Beijing Co., Ltd.
PINK:PHBBF
|
$2.34 Billion |
|
DSFIY
PINK:DSFIY
|
$2.34 Billion |
|
Premium Brands Holdings Corporation
PINK:PRBZF
|
$2.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shijiazhuang Yiling Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,449,722,316 to 10,223,487,732, a change of -1,226,234,584 (-10.7%).
- Net loss of 724,515,581 reduced equity.
- Dividend payments of 375,305,427 reduced retained earnings.
- Other factors decreased equity by 126,413,576.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-724.52 Million | -7.09% |
| Dividends Paid | CN¥375.31 Million | -3.67% |
| Other Changes | CN¥-126.41 Million | -1.24% |
| Total Change | CN¥- | -10.71% |
Book Value vs Market Value Analysis
This analysis compares Shijiazhuang Yiling Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.76x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 42.14x to 2.76x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.40 | CN¥16.89 | x |
| 2009-12-31 | CN¥0.66 | CN¥16.89 | x |
| 2010-12-31 | CN¥0.89 | CN¥16.89 | x |
| 2011-12-31 | CN¥2.62 | CN¥16.89 | x |
| 2012-12-31 | CN¥2.51 | CN¥16.89 | x |
| 2013-12-31 | CN¥2.74 | CN¥16.89 | x |
| 2014-12-31 | CN¥2.94 | CN¥16.89 | x |
| 2015-12-31 | CN¥3.04 | CN¥16.89 | x |
| 2016-12-31 | CN¥3.35 | CN¥16.89 | x |
| 2017-12-31 | CN¥4.23 | CN¥16.89 | x |
| 2018-12-31 | CN¥4.51 | CN¥16.89 | x |
| 2019-12-31 | CN¥4.76 | CN¥16.89 | x |
| 2020-12-31 | CN¥5.34 | CN¥16.89 | x |
| 2021-12-31 | CN¥5.43 | CN¥16.89 | x |
| 2022-12-31 | CN¥6.54 | CN¥16.89 | x |
| 2023-12-31 | CN¥6.85 | CN¥16.89 | x |
| 2024-12-31 | CN¥6.12 | CN¥16.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shijiazhuang Yiling Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.12%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.30x
- Recent ROE (-7.09%) is below the historical average (12.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 25.36% | 13.01% | 1.13x | 1.73x | CN¥73.97 Million |
| 2009 | 37.73% | 18.21% | 1.08x | 1.92x | CN¥218.41 Million |
| 2010 | 28.92% | 19.13% | 0.93x | 1.62x | CN¥206.46 Million |
| 2011 | 12.27% | 23.25% | 0.46x | 1.14x | CN¥83.91 Million |
| 2012 | 4.83% | 11.27% | 0.40x | 1.08x | CN¥-198.69 Million |
| 2013 | 5.74% | 9.81% | 0.53x | 1.09x | CN¥-181.54 Million |
| 2014 | 7.78% | 12.14% | 0.57x | 1.12x | CN¥-100.91 Million |
| 2015 | 8.94% | 13.52% | 0.56x | 1.19x | CN¥-51.07 Million |
| 2016 | 10.01% | 13.84% | 0.62x | 1.17x | CN¥502.49K |
| 2017 | 7.60% | 13.25% | 0.52x | 1.11x | CN¥-170.31 Million |
| 2018 | 7.93% | 12.45% | 0.56x | 1.13x | CN¥-156.89 Million |
| 2019 | 7.63% | 10.41% | 0.64x | 1.14x | CN¥-187.94 Million |
| 2020 | 13.66% | 13.88% | 0.76x | 1.29x | CN¥326.81 Million |
| 2021 | 14.82% | 13.28% | 0.78x | 1.42x | CN¥436.94 Million |
| 2022 | 21.61% | 18.85% | 0.77x | 1.49x | CN¥1.27 Billion |
| 2023 | 11.81% | 13.11% | 0.61x | 1.48x | CN¥207.41 Million |
| 2024 | -7.09% | -11.12% | 0.49x | 1.30x | CN¥-1.75 Billion |
Industry Comparison
This section compares Shijiazhuang Yiling Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) | CN¥10.70 Billion | 25.36% | 0.33x | $2.34 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |